188 Background: Abiraterone or enzalutamide are licensed for use post-docetaxel in
metastatic castrate resistant prostate cancer (mCRPC). Both target the androgen receptor …

Docetaxel in combination with prednisone is the standard of care in men with symptomatic
castration-resistant prostate cancer (CRPC). However, a substantial proportion of men with …

As recently as 2004, treatment options for men with metastatic castration-resistant prostate
cancer (mCRPC) were limited, with docetaxel the only approved agent conferring a survival …

Background Once castration resistance is documented and secondary hormone therapy is
ineffective, standard treatment of metastatic prostate cancer is docetaxel, with …

Objective To evaluate the benefit of docetaxel rechallenge in patients with metastatic
castration‐resistant prostate cancer (mCRPC) relapsing after an initial good response to first …

Objectives To report long‐term outcome survival analysis of docetaxel‐based chemotherapy
combined with dexamethasone in castration‐resistant prostate cancer patients (Japan …

5063 Background: Recently, several new drugs have demonstrated an overall survival (OS)
benefit in patients (pts) with mCRPC. Their use must be optimized to maximize patient …

Objectives: Management of castration-resistant prostate cancer after docetaxel has become
an unmet need for which various agents have been investigated. We report our experience …

Six different treatments have demonstrated improved survival in phase III trials targeted to
patients with metastatic castration-resistant prostate cancer (mCRPC). Front-line therapeutic …

Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall
survival (OS) is significantly improved with cabazitaxel versus mitoxantrone after prior …